- $49.19m
- $37.73m
- $62.66m
- 81
- 49
- 13
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.39 | ||
| Price to Tang. Book | 1.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.9 | ||
| EV to EBITDA | 109.62 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.29% | ||
| Return on Equity | -3.05% | ||
| Operating Margin | -3.95% | ||
Financial Summary
| Year End 31st May | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 39.48 | 46.36 | 57.68 | 66.15 | 62.66 | n/a | n/a | 11.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -22.98 | +53.71 | +49.52 | -16.89 | -84.12 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BIOQUAL, Inc. provides contract research services primarily focused on animal models of human diseases including acquired immunodeficiency syndrome (AIDS), influenza, respiratory syncytial virus (RSV) infection, coronavirus infections (including COVID-19), flavivirus infections (including Zika and Dengue), malaria, hepatitis, cancer, and other infectious diseases. It also performs in vitro contract research services. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. Its services also encompass sample processing and custom assays for serology, cell-mediated immunity, viral loads, and bacterial enumeration. Its model services also include syngeneic mouse tumor allograft and select human cell line derived xenograft (CDX) models, and it offers GLP-compliant preclinical testing services in various small animal models. It provides its services to the federal government, universities and the life science and pharmaceutical industries.
Directors
- Mark Lewis CHM
- David Newcomer CFO (48)
- MITCH FRANKLIN VOP
- Chander Sarma VPR
- Nancy Madden VAD
- Hanne Andersen DRC
- David Landon DRC (54)
- Last Annual
- May 31st, 2023
- Last Interim
- November 30th, 2024
- Incorporated
- January 5th, 1982
- Public Since
- July 14th, 1983
- No. of Employees
- 108
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 894,416
- Address
- 9600 Medical Center Drive, Suite 101, ROCKVILLE, 20850-3336
- Web
- https://www.bioqual.com/
- Phone
- +1 2404047654
- Auditors
- Aronson & Co
Upcoming Events for BIOQ
Q1 2026 Bioqual Inc Earnings Release
Similar to BIOQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Bioqual share price?
As of Today at 19:36 UTC, shares in Bioqual are trading at $55.00. This share price information is delayed by 15 minutes.
How has the Bioqual share price performed this year?
Shares in Bioqual last closed at $55.00 and the price had moved by -31.25% over the past 365 days. In terms of relative price strength the Bioqual share price has underperformed the S&P500 Index by -36.25% over the past year.
What are the analyst and broker recommendations for Bioqual?
There is no consensus recommendation for this security.
Find out moreWhat is the Bioqual dividend yield?
The Bioqual dividend yield is 0.91% based on the trailing twelve month period.
Does Bioqual pay a dividend?
Last year, Bioqual paid a total dividend of $0.50, and it currently has a trailing dividend yield of 0.91%. We do not have any data on when Bioqual is to next pay dividends.
When does Bioqual next pay dividends?
We do not have data on when Bioqual is to next pay dividends. The historic dividend yield on Bioqual shares is currently 0.91%.
How do I buy Bioqual shares?
To buy shares in Bioqual you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bioqual?
As of the previous close price of $55.00, shares in Bioqual had a market capitalisation of $49.19m.
Where are Bioqual shares listed?
Here are the trading details for Bioqual:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BIOQ
What kind of share is Bioqual?
Based on an overall assessment of its quality, value and momentum Bioqual is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bioqual share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Bioqual share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioqual. Over the past six months, its share price has underperformed the S&P500 Index by -18.3%.
As of the last closing price of $55.00, shares in Bioqual were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bioqual PE Ratio?
The Bioqual PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $55.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bioqual?
Bioqual's management team is headed by:
- Mark Lewis - CHM
- David Newcomer - CFO
- MITCH FRANKLIN - VOP
- Chander Sarma - VPR
- Nancy Madden - VAD
- Hanne Andersen - DRC
- David Landon - DRC